Pediatric Sepsis. Challenges and Adjunctive Therapies.

Critical Care Clinics

Volumn 29, Issue 2, 2013, Pages 203-222

  Hanna, William ^a   Wong, Hector R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antibiotics; Corticosteroids; Epidemiology; Hemoadsorption; Hemofiltration; Outcomes; Plasmapheresis; Quality improvement

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; CORTICOTROPIN; HYDROCORTISONE; METHYLPREDNISOLONE;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; CHILDHOOD MORTALITY; COMORBIDITY; CORTICOTROPIN BLOOD LEVEL; DISEASE MARKER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; GENETIC ASSOCIATION; HEMADSORPTION; HEMOFILTRATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CHILD; COMBINED MODALITY THERAPY; CRITICAL CARE; EXTRACORPOREAL CIRCULATION; FLUID THERAPY; HEMOFILTRATION; HEMOPERFUSION; HOSPITAL MORTALITY; HUMANS; HYDROCORTISONE; PLASMAPHERESIS; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84875591100     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.11.003     Document Type: Review

References (98)

1. Wong H.R., Nowak J.E., Standage S., et al. Sepsis and septic shock. Pediatric critical care medicine 2011, 1413-1429. Mosby, St Louis (MO). 4th edition. B.P. Fuhrman, J.J. Zimmerman (Eds.).
2. Cornell T.T., Wynn J., Shanley T.P., et al. Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics 2010, 125:1248-1258.
3. Wynn J.L., Wong H.R. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol 2010, 37:439-479.
4. Wynn J., Cornell T.T., Wong H.R., et al. The host response to sepsis and developmental impact. Pediatrics 2010, 125:1031-1041.
5. Brierley J., Carcillo J.A., Choong K., et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009, 37:666-688.
6. Watson R.S., Carcillo J.A., Linde-Zwirble W.T., et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003, 167:695-701.
7. Watson R.S., Carcillo J.A. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005, 6:S3-S5.
8. Marcin J.P., Pollack M.M. Review of the acuity scoring systems for the pediatric intensive care unit and their use in quality improvement. J Intensive Care Med 2007, 22:131-140.
9. Vincent J.L., Opal S.M., Marshall J.C. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med 2010, 38:283-287.
10. Wong H.R., Salisbury S., Xiao Q., et al. The pediatric sepsis biomarker risk model. Crit Care 2012, 16:R174.
11. Kaplan J.M., Wong H.R. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011, 12:165-173.
12. Quartin A.A., Schein R.M., Kett D.H., et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997, 277:1058-1063.
13. Karlsson S., Ruokonen E., Varpula T., et al. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009, 37:1268-1274.
14. Czaja A.S., Zimmerman J.J., Nathens A.B. Readmission and late mortality after pediatric severe sepsis. Pediatrics 2009, 123:849-857.
15. Pollack M.M., Holubkov R., Glass P., et al. Functional Status Scale: new pediatric outcome measure. Pediatrics 2009, 124:e18-e28.
16. Levy M.M., Dellinger R.P., Townsend S.R., et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010, 38:367-374.
17. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
18. Kumar A., Haery C., Paladugu B., et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006, 193:251-258.
19. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
20. Puskarich M.A., Trzeciak S., Shapiro N.I., et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011, 39:2066-2071.
21. Muszynski J.A., Knatz N.L., Sargel C.L., et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J 2011, 30:295-301.
22. Cruz A.T., Perry A.M., Williams E.A., et al. Implementation of goal-directed therapy for children with suspected sepsis in the emergency department. Pediatrics 2011, 127:e758-e766.
23. Carcillo J.A., Davis A.L., Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991, 266:1242-1245.
24. Han Y.Y., Carcillo J.A., Dragotta M.A., et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003, 112:793-799.
25. de Oliveira C.F., de Oliveira D.S., Gottschald A.F., et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med 2008, 34:1065-1075.
26. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
27. Smith S.H., Perner A. Higher vs. lower fluid volume for septic shock: clinical characteristics and outcome in unselected patients in a prospective, multicenter cohort. Crit Care 2012, 16:R76.
28. Hilton A.K., Bellomo R. A critique of fluid bolus resuscitation in severe sepsis. Crit Care 2012, 16:302.
29. Vincent J.L., Sakr Y., Sprung C.L., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
30. Boyd J.H., Forbes J., Nakada T.A., et al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011, 39:259-265.
31. Murphy C.V., Schramm G.E., Doherty J.A., et al. The importance of fluid management in acute lung injury secondary to septic shock. Chest 2009, 136:102-109.
32. Goldstein S.L., Somers M.J., Baum M.A., et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005, 67:653-658.
33. Maitland K., Kiguli S., Opoka R.O., et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011, 364:2483-2495.
34. Duke T. What the African fluid-bolus trial means. Lancet 2011, 378:1685-1687.
35. Russell J.A. How much fluid resuscitation is optimal in septic shock?. Crit Care 2012, 16:146.
36. Prigent H., Maxime V., Annane D. Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 2004, 8:243-252.
37. Hebbar K., Rigby M.R., Felner E.I., et al. Neuroendocrine dysfunction in pediatric critical illness. Pediatr Crit Care Med 2009, 10:35-40.
38. Menon K., Ward R.E., Lawson M.L., et al. A prospective multicenter study of adrenal function in critically ill children. Am J Respir Crit Care Med 2010, 182:246-251.
39. Casartelli C.H., Garcia P.C., Branco R.G., et al. Adrenal response in children with septic shock. Intensive Care Med 2007, 33:1609-1613.
40. Hebbar K.B., Stockwell J.A., Leong T., et al. Incidence of adrenal insufficiency and impact of corticosteroid supplementation in critically ill children with systemic inflammatory syndrome and vasopressor-dependent shock. Crit Care Med 2011, 39:1145-1150.
41. Pizarro C.F., Troster E.J., Damiani D., et al. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med 2005, 33:855-859.
42. Sarthi M., Lodha R., Vivekanandhan S., et al. Adrenal status in children with septic shock using low-dose stimulation test. Pediatr Crit Care Med 2007, 8:23-28.
43. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
44. Marik P.E., Pastores S.M., Annane D., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937-1949.
45. Lefering R., Neugebauer E.A. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995, 23:1294-1303.
46. Cronin L., Cook D.J., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430-1439.
47. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987, 317:659-665.
48. Min M., U T., Aye M., et al. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health 1975, 6:573-579.
49. Tassniyom S., Vasanawathana S., Chirawatkul A., et al. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 1993, 92:111-115.
50. Sumarmo, Talogo W., Asrin A., et al. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 1982, 69:45-49.
51. Slusher T., Gbadero D., Howard C., et al. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatr Infect Dis J 1996, 15:579-583.
52. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038-1045.
53. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124.
54. Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensive Care 2011, 1:7.
55. Markovitz B.P., Goodman D.M., Watson R.S., et al. A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids?. Pediatr Crit Care Med 2005, 6:270-274.
56. Zimmerman J.J., Williams M.D. Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. Pediatr Crit Care Med 2011, 12:2-8.
57. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843.
58. Zimmerman J.J. A history of adjunctive glucocorticoid treatment for pediatric sepsis: moving beyond steroid pulp fiction toward evidence-based medicine. Pediatr Crit Care Med 2007, 8:530-539.
59. Zimmerman J.J., Donaldson A., Barker R.M., et al. Real-time free cortisol quantification among critically ill children. Pediatr Crit Care Med 2011, 12:525-531.
60. Wong H.R., Cvijanovich N.Z., Allen G.L., et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med 2011, 39:2511-2517.
61. Wong H.R., Wheeler D.S., Tegtmeyer K., et al. Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med 2010, 38:1955-1961.
62. Wong H.R., Cvijanovich N., Lin R., et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009, 7:34.
63. Rimmele T., Kellum J.A. Clinical review: blood purification for sepsis. Crit Care 2011, 15:205.
64. Payen D., Mateo J., Cavaillon J.M., et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009, 37:803-810.
65. Sander A., Armbruster W., Sander B., et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997, 23:878-884.
66. Cole L., Bellomo R., Hart G., et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002, 30:100-106.
67. De Vriese A.S., Colardyn F.A., Philippe J.J., et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999, 10:846-853.
68. Cole L., Bellomo R., Journois D., et al. High-volume haemofiltration in human septic shock. Intensive Care Med 2001, 27:978-986.
69. Honore P.M., Jacobs R., Boer W., et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 2012, 33:44-51.
70. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361:1627-1638.
71. Rimmele T., Kellum J.A. High-volume hemofiltration in the intensive care unit: a blood purification therapy. Anesthesiology 2012, 116:1377-1387.
72. Fleming G.M., Walters S., Goldstein S.L., et al. Nonrenal indications for continuous renal replacement therapy: a report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. Pediatr Crit Care Med 2012, 13:e299-e304.
73. Goldstein S.L. Advances in pediatric renal replacement therapy for acute kidney injury. Semin Dial 2011, 24:187-191.
74. Sutherland S.M., Zappitelli M., Alexander S.R., et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010, 55:316-325.
75. Zappitelli M., Goldstein S.L., Symons J.M., et al. Protein and calorie prescription for children and young adults receiving continuous renal replacement therapy: a report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. Crit Care Med 2008, 36:3239-3245.
76. Flores F.X., Brophy P.D., Symons J.M., et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol 2008, 23:625-630.
77. Hackbarth R., Bunchman T.E., Chua A.N., et al. The effect of vascular access location and size on circuit survival in pediatric continuous renal replacement therapy: a report from the PPCRRT registry. Int J Artif Organs 2007, 30:1116-1121.
78. Naran N., Sagy M., Bock K.R. Continuous renal replacement therapy results in respiratory and hemodynamic beneficial effects in pediatric patients with severe systemic inflammatory response syndrome and multiorgan system dysfunction. Pediatr Crit Care Med 2010, 11:737-740.
79. Brochard L., Abroug F., Brenner M., et al. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010, 181:1128-1155.
80. Shoji H., Tani T., Hanasawa K., et al. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther Apher 1998, 2:3-12.
81. Tani T., Shoji H., Guadagni G., et al. Extracorporeal removal of endotoxin: the polymyxin B-immobilized fiber cartridge. Contrib Nephrol 2010, 167:35-44.
82. Cruz D.N., Antonelli M., Fumagalli R., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301:2445-2452.
83. Cruz D.N., Perazella M.A., Bellomo R., et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007, 11:R47.
84. Morishita Y., Kita Y., Ohtake K., et al. Successful treatment of sepsis with polymyxin B-immobilized fiber hemoperfusion in a child after living donor liver transplantation. Dig Dis Sci 2005, 50:757.
85. Baldwin G., Alpert G., Caputo G.L., et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis 1991, 164:542-549.
86. Nguyen T.C., Kiss J.E., Goldman J.R., et al. The role of plasmapheresis in critical illness. Crit Care Clin 2012, 28:453-468.
87. Stegmayr B.G., Banga R., Berggren L., et al. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003, 31:1730-1736.
88. Busund R., Koukline V., Utrobin U., et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002, 28:1434-1439.
89. van Deuren M., Santman F.W., van Dalen R., et al. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992, 15:424-430.
90. Gardlund B., Sjolin J., Nilsson A., et al. Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis 1993, 25:757-761.
91. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325:393-397.
92. Zheng X.L., Kaufman R.M., Goodnough L.T., et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103:4043-4049.
93. Nguyen T.C., Han Y.Y., Kiss J.E., et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008, 36:2878-2887.
94. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2010, 25:83-177.
95. Fortenberry J.D., Paden M.L. Extracorporeal therapies in the treatment of sepsis: experience and promise. Semin Pediatr Infect Dis 2006, 17:72-79.
96. Wong H.R. Genetics and genomics in pediatric septic shock. Crit Care Med 2012, 40:1618-1626.
97. Wong H.R. Clinical review: sepsis and septic shock-the potential of gene arrays. Crit Care 2012, 16:204.
98. Che D., Liu Q., Rasheed K., et al. Decision tree and ensemble learning algorithms with their applications in bioinformatics. Adv Exp Med Biol 2011, 696:191-199.